Cervical cancer subtypes harbouring integrated and/or episomal HPV16 portray distinct molecular phenotypes based on transcriptome profiling of mRNAs and miRNAs.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
2019
2019
Historique:
received:
06
12
2018
revised:
03
02
2019
accepted:
13
02
2019
entrez:
3
4
2019
pubmed:
3
4
2019
medline:
3
4
2019
Statut:
epublish
Résumé
Heterogeneity in cervical cancers (CaCx) in terms of HPV16 physical status prompted us to investigate the mRNA and miRNA signatures among the different categories of CaCx samples. We performed microarray-based mRNA expression profiling and quantitative real-time PCR-based expression analysis of some prioritised miRNAs implicated in cancer-related pathways among various categories of cervical samples. Such samples included HPV16-positive CaCx cases that harboured either purely integrated HPV16 genomes (integrated) and those that harboured episomal viral genomes, either pure or concomitant with integrated viral genomes (episomal), which were compared with normal cervical samples that were either HPV negative or positive for HPV16. The mRNA expression profile differed characteristically between integrated and episomal CaCx cases for enriched biological pathways. miRNA expression profiles also differed among CaCx cases compared with controls (upregulation-miR-21, miR-16, miR-205, miR-323; downregulation-miR-143, miR-196b, miR-203, miR-34a; progressive upregulation-miR-21 and progressive downregulation-miR-143, miR-34a, miR-196b and miR-203) in the order of HPV-negative controls, HPV16-positive non-malignant samples and HPV16-positive CaCx cases. miR-200a was upregulated in HPV16-positive cervical tissues irrespective of histopathological status. Expression of majority of the predicted target genes was negatively correlated with their corresponding miRNAs, irrespective of the CaCx subtypes. E7 mRNA expression correlated positively with miR-323 expression among episomal cases and miR-203, among integrated cases. miR-181c expression was downregulated only among the episomal CaCx cases and negatively correlated with protein coding transcript of the proliferative target gene,
Identifiants
pubmed: 30937183
doi: 10.1038/s41420-019-0154-x
pii: 154
pmc: PMC6433907
doi:
Types de publication
Journal Article
Langues
eng
Pagination
81Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interest.
Références
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3159-63
pubmed: 1313584
Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2999-3004
pubmed: 14973191
Gynecol Oncol. 2004 Apr;93(1):41-8
pubmed: 15047212
Oncogene. 2005 Jan 10;24(2):287-91
pubmed: 15640844
Oncogene. 2005 Sep 15;24(41):6222-30
pubmed: 16103886
Gynecol Oncol. 2006 Feb;100(2):372-8
pubmed: 16246404
Cancer Res. 2006 Aug 1;66(15):7390-4
pubmed: 16885332
Virology. 2006 Oct 25;354(2):280-5
pubmed: 16905170
Int J Gynecol Cancer. 2007 Jan-Feb;17(1):107-17
pubmed: 17291240
Tissue Antigens. 2007 Oct;70(4):283-93
pubmed: 17767549
Oncogene. 2008 Jan 24;27(5):565-73
pubmed: 17891185
Virology. 2008 Jul 20;377(1):143-50
pubmed: 18495198
Nature. 2008 Aug 7;454(7205):780-3
pubmed: 18596690
Cell. 2009 Jan 23;136(2):215-33
pubmed: 19167326
Virology. 2010 Jun 20;402(1):197-202
pubmed: 20394955
Annu Rev Microbiol. 2010;64:123-41
pubmed: 20477536
PLoS One. 2010 May 12;5(5):e10615
pubmed: 20485546
Cancer Res. 2010 Jul 1;70(13):5226-37
pubmed: 20551052
J Virol. 2010 Oct;84(20):10644-52
pubmed: 20702634
Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):2754-9
pubmed: 21697511
PLoS One. 2012;7(9):e44678
pubmed: 22970286
Adv Exp Med Biol. 2013;774:1-20
pubmed: 23377965
PLoS One. 2013 Jun 06;8(6):e65647
pubmed: 23762404
Asian Pac J Cancer Prev. 2013;14(5):3041-4
pubmed: 23803076
APMIS. 2014 Mar;122(3):206-14
pubmed: 23879533
Mol Cell Proteomics. 2014 Feb;13(2):397-406
pubmed: 24309898
J Hematol Oncol. 2014 Jan 10;7:6
pubmed: 24405714
Asian Pac J Cancer Prev. 2014;15(4):1675-9
pubmed: 24641388
PLoS One. 2014 May 30;9(5):e97842
pubmed: 24879114
Mol Cell Biol. 2014 Oct;34(20):3780-7
pubmed: 25047834
Curr Genomics. 2014 Aug;15(4):310-23
pubmed: 25132800
J Biol Chem. 2015 Jan 23;290(4):2198-212
pubmed: 25477524
Oncol Lett. 2015 Apr;9(4):1691-1698
pubmed: 25789025
Neoplasma. 2015;62(4):550-9
pubmed: 25997962
Sci Rep. 2015 Jul 08;5:11724
pubmed: 26152361
Cell Physiol Biochem. 2015;36(4):1491-8
pubmed: 26160610
Molecules. 2015 Jul 21;20(7):13226-39
pubmed: 26197311
Oncol Rep. 2016 Apr;35(4):2297-305
pubmed: 26797462
BMC Cancer. 2016 Jul 04;16:382
pubmed: 27377959
Cell Oncol (Dordr). 2016 Dec;39(6):559-572
pubmed: 27683269
Oncotarget. 2017 Feb 21;8(8):13375-13386
pubmed: 28077784
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
Biomed Pharmacother. 2018 Jan;97:528-534
pubmed: 29091904